The company will enhance accessibility to medicines for Egypt, the Middle East and Africa while strengthening regional and local manufacturing capacities
ProBioGen and Minapharm Pharmaceuticals have announced the incorporation of a ProBioGen subsidiary, MiGenTra, with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. The incorporation accelerates ProBioGen's 2030 growth roadmap and demonstrates the company’s intent to diversify its business.
The company will enhance accessibility to medicines for Egypt, the Middle East and Africa while strengthening regional and local manufacturing capacities, ProBioGen claims. It will support efforts by the World Health Organization (WHO) and the International Finance Corporation (IFC) to respond to unmet medical needs in the region.
MiGenTra combines the scientific and manufacturing expertise from both contributing companies. It is established for product development and commercialisation in the field of biosimilars, cell and gene therapies (CGT) and vaccines, capitalising on ProBioGen’s development capabilities and Minapharm’s positioning in the region.
"Healthcare is not a privilege but a human right", said Lutz Hilbrich, MD MBA and CEO of ProBioGen. "By creating MiGenTra we exemplify our commitment to overcome inequalities. ProBioGen has been for a while on a growth path. With the formation of MiGenTra we aim to further accelerate our growth while transforming the lives of millions in urgent medical need through state of the art medicines at affordable prices. I am honoured to take on the CEO position for this newly built entity. We are committed to contributing to the transformational change across healthcare in the African continent."
Wafik Bardissi, PhD, Chairman and CEO of Minapharm Pharmaceuticals added: "MiGenTra marks a starting point of practice to consolidate an international platform of intelligent biopharmaceutical technologies with a longstanding regional process development and manufacturing expertise in the Middle East and Africa. Minapharm has demonstrated the feasibility of aligning economic interests and equality in access to affordable complex genetically engineered medicines. The COVID-19 pandemic has once again exposed global inequalities the world has ignored for too long. MiGenTra pledges to ensure equitable access to essential medicines, thereby contributing to the Global Health Initiative."